



Maintaining its turnaround story via improvements in its core business, ramp up, and capacity expansions; upgrade to “Overweight”

MEH continues to ramp up its expansions as it seeks to also extend its operational beds by a scheduled 250 beds to roll out during FY24. Along with a 194 bed brownfield expansion in its flagship Jeddah facility, we see revenue in support to grow by an FY23-28E CAGR of 9.6%. A foothold in the Western region and holy sites is another source of revenue support amid Vision 2030 initiatives. Furthermore, we expect margins to improve in the long run on the back of ramping up facilities and cost efficiency initiatives by the firm. We expect GP margins to remain in a range of 38.5% to 39.9% from FY24-28 before improving gradually onwards. Similarly we expect operating margins to reach 15.4% (FY28) from 12.9%, yet facing some pressures during FY26's Jeddah expansion. MEH still holds the highest net D/E in the sector, and we expect its financing cost to peak in FY24 at historical highs before deleveraging gradually over the coming years. We see that their debt needs will wind down amid improved financial performance to reach 0.3x D/E in FY28E from 1.6x in FY23. However, as government entities constitute 97% of the firm's receivables, delays in payments could spur financing needs towards working capital. We find the stock on its way to its continued turnaround, with significant upside risk if margins recover to past levels seen during 2014-16. At FY25 forward PE of 24.5x we upgrade our recommendation to “Overweight” at a revised TP of SAR 92.0 per share.

Planned beds capacity expansions to drive revised immediate-term and medium term revenue growth outlook- and amid Vision 2030 pilgrimage targets: MEH's FY24E's revenue is driven by a 250 bed operational addition in its existing Riyadh (+50 beds), and Dammam (+100 beds), and Makkah (+100 beds) capacities. We estimate a 14.0% growth in its current capacity of 1,434 beds by FY24's end. Some of the 250 bed expansions are expected to roll out gradually into the next year as well; translating into an FY23-25E revenue CAGR of 12.1%, reaching SAR 3,333mn in FY25 from SAR 2,653mn in FY23. Furthermore, Jeddah's FY26 brownfield expansion will add a planned 194 beds at the group's figurehead facility. The group's foothold in the Western region, where 50% of its revenue is generated, is also expected to benefit from increased footfall in the region amid Vision 2030 pilgrim targets of 30mn visitors (from 13.6mn in FY23). We estimate the group to generate an 9.6% revenue CAGR from FY23-28E driven by expansions and supported by Western region footfall.

Value based health care model to improve GP margins gradually as facilities ramp up; significant upside risk if margins recover to past levels seen during FY14-16: We expect the cost efficiency focus at MEH to edge GP Margins towards near FY17 levels while facing pressures of expansions along the way. We anticipate GP margins to expand by c. 90bps from FY23 to reach 39.1% in FY25 before facing some pressures during FY26 amid the brownfield expansion in Jeddah building new capacities. We expect GP margins to remain in a range of 38.5% to 39.9% from FY24-28 before improving gradually onwards. We believe that the stock offers significant upside risk to investors should margins recover to past levels seen during FY14-16, which were reported in the ranges of early 50's (%). Should MEH tend closer to these ranges, as due to a combination of price increases, operational efficiency, and successful ramp ups and utilization; the stock can benefit tremendously from changes in margins. A hypothetical 50% GP margin for FY28 (which has been previously surpassed), could result in an additional SAR 4.6 EPS to that year from our estimates. Furthermore, we expect a similar trajectory from operating margins, expanding 1.6 percentage points from FY23-25E to reach 14.5%, from 12.9%, before dipping to 13.8% in FY26 and improving gradually thereafter. We are anticipating OPEX to revenues to reach 24.5% in FY28, at a gradual improvement from FY23's 25.3%, while treating Q1-24's SAR 33.1mn ECL reversal as a one off event.

Highly leveraged balance sheet amid Sukuk issuance; finance costs expected to peak at highest levels; further deleveraging and decrease in finance costs could unlock value for shareholders: We expect finance costs for MEH to peak in FY24 to reach SAR 204.1mn post its SAR 1bn Sukuk issuance. However, the firm's leverage needs are expected to begin winding down amid improvements in its CFO generation, yet still requiring a need for debt ahead of the expansions scheduled. Debt to equity levels are anticipated to fall from 1.6x in FY23 to 1.3x in FY24 before unwinding at a quicker rate thereafter. Furthermore, should MEH redeems its Sukuk earlier than maturity, or partially redeems it amid the emergence of deflationary global macro data, MEH's interest rate costs could decrease further; MEH carries the highest net debt to equity in the sector among its peers at 1.42x, as compared to the 0.29x sector median.

Recommendation **Overweight**

Target Price (SAR) **92.0**

Upside / (Downside)* **10.2%**

Source: Tadawul *prices as of 24th of June 2024

Key Financials

SARmn (unless specified)	FY22	FY23	FY24E	FY25E
Revenues	2,152	2,653	3,009	3,333
Growth %	14.9%	23.3%	13.4%	10.7%
Net Income	75.2	180.2	239.6	313.4
Growth %	337.1%	139.7%	33.0%	30.8%
EPS	0.82	1.96	2.60	3.41

Source: Company reports, Aljazira Capital

Key Ratios

	FY22	FY23	FY24E	FY25E
Gross Margin	31.6%	38.2%	38.6%	39.1%
Net Margin	3.5%	6.8%	8.0%	9.4%
RoA	1.8%	3.7%	4.6%	5.9%
RoE	5.6%	12.1%	14.2%	16.0%
P/E (x)	31.2	42.6	32.1	24.5
P/B (x)	1.7	5.0	4.4	3.7
EV/EBITDA (x)	16.8	19.5	16.3	14.7
Dividend Yield	0.0%	0.0%	0.0%	0.0%


Source: Company reports, Aljazira Capital

Key Market Data

Market Cap (SAR bn)	7.67
YTD%	-4.6%
52 weeks (High)/(Low)	134.4 /51.5
Share Outstanding (bn)	92.04

Source: Company reports, Aljazira Capital

Price Performance



Source: Tadawul, Aljazira Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa






Working capital faces risk from MOH delayed repayments and could spur further need for working capital funding: Government agencies make up nearly 97% of MEH's receivables despite the MOH making up only 54% of revenues; an MOH payment delay was then able to caused FY23 receivable days to increase to 270.7 days from 247.4 the year before. However, we see the working capital risk under control when stepping back to observe a decrease in its cash conversion cycle days for that same period (171.3 days from 179.6 days) as a result of improved inventory and payable efficiency. While MOH payment days remain a risk on the firm's cash needs, and could warrant further needs for debts, the firm saw a repayment from its MOH receivables to record a SAR 33.1mn reversal in ECL while holding an ECL to receivables at 3.0%, down from 4.1% at FY23's end.


AJC view and valuation: MEH presents investors as a stock with a turnaround story to become a more financially attractive vehicle; the firm is a large scale provider hosting the second highest number of beds in the sector, with expansion plans further underway to increase its expected capacity by 31% from its current 1,434 beds to reach an expected 1878 beds by FY27's end. Therefore, we categorize the coming years of MEH as a period of ramping up and turning around from its previously strained performance from greenfield and brownfield capacity expansion. As a result, the coming periods can be summarized by its expected expansions in ROAE from 12.1% in FY23 to 17.9% in FY28, attributed to margin efficiencies and increased revenue driven by urban area operational capacity expansions and footfall in the Western region. We expect the improved conditions at MEH could possibly spur a dividend payout of SAR 1.0 per share by FY27. We value the stock using a blended, 60% DCF valuation (WACC = 8.2% and terminal growth rate = 2.5%) and 40% on PE valuations (31.0x on FY25E estimates) to arrive at an **"Overweight"** recommendation at an upgraded TP of **SAR 92.0 per share**.

Fig 1. Performance to be carried by expansions and margin efficiency, in support of decreased financing costs



Sources: Aljazira Capital, Company Financials

Fig 2. Expected beds and roll out; capacity expansions to come from brownfield and operational beds increases



Sources: Aljazira Capital, Company Disclosures





Key Financial Data

Amount in SAR mn, unless otherwise specified	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	FY27E	FY28E
Income statement									
Revenues	1,750.6	1,872.6	2,151.7	2,653.2	3,009.4	3,332.6	3,688.0	3,994.3	4,198.7
Y/Y	17.0%	7.0%	14.9%	23.3%	13.4%	10.7%	10.7%	8.3%	5.1%
Cost	(1,172.2)	(1,264.4)	(1,471.7)	(1,638.8)	(1,848.6)	(2,030.9)	(2,269.2)	(2,429.9)	(2,523.4)
Gross profit	578.4	608.2	680.0	1,014.4	1,160.8	1,301.7	1,418.9	1,564.4	1,675.3
Selling & distribution expense	(31.1)	(46.0)	(30.4)	(51.1)	(58.3)	(65.1)	(71.8)	(77.9)	(81.9)
General & administration expense	(439.8)	(508.0)	(509.3)	(620.8)	(662.6)	(752.9)	(839.9)	(896.5)	(947.4)
Operating profit	107.4	54.2	140.3	342.5	439.9	483.7	507.1	589.9	646.0
Y/Y	4.0%	-49.5%	158.7%	144.0%	28.4%	9.9%	4.8%	16.3%	9.5%
Other income	7.5	12.0	9.5	14.7	33.8	37.4	41.4	44.8	47.1
Financial charges	(34.2)	(47.0)	(68.7)	(155.6)	(204.1)	(171.6)	(132.8)	(92.1)	(59.2)
Profit before zakat & minority interest	80.7	19.2	81.2	201.6	269.5	349.4	415.7	542.6	633.9
Non-controlling interest	6.8	5.5	3.6	3.5	3.2	4.6	5.7	7.4	8.7
Profit before zakat	75.2	11.7	71.6	183.6	242.8	318.0	378.3	493.8	583.2
Zakat	(5.5)	(7.5)	(9.6)	(18.0)	(26.7)	(31.4)	(37.4)	(48.8)	(50.7)
Net income	82.0	17.2	75.2	180.2	239.6	313.4	372.6	486.4	574.4
Y/Y	-16.0%	-79.0%	337.1%	139.7%	33.0%	30.8%	18.9%	30.5%	18.1%
EPS (SAR)	0.9	0.2	0.8	2.0	2.6	3.4	4.0	5.3	6.2
DPS (SAR)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.50
Balance sheet									
Assets									
Cash & bank balance	17	28	16	44	80	41	53	53	284
Other current assets	1,476	1,548	1,941	2,530	2,421	2,575	2,765	2,909	2,993
Property & Equipment	2,074	2,357	2,471	2,502	2,623	2,718	2,736	2,729	2,721
Other non-current assets	33	40	71	96	78	69	60	51	41
Total assets	3,599	3,972	4,499	5,173	5,202	5,403	5,614	5,742	6,039
Liabilities & owners' equity									
Total current liabilities	1,188	1,367	1,631	2,003	1,308	1,400	1,430	1,463	1,418
Long-term loans	847	1,028	1,181	1,310	1,835	1,618	1,405	999	850
Total other non-current liabilities	290	282	280	295	254	268	289	303	312
Non-controlling interest	43	38	43	46	46	46	46	46	46
Paid -up capital	920	920	920	920	920	920	920	920	920
Statutory reserves	192	194	201	219	243	274	312	360	418
Retained earnings	119	144	243	377	593	875	1,210	1,648	2,073
Total owners' equity	1,232	1,258	1,364	1,517	1,757	2,070	2,443	2,929	3,411
Total equity & liabilities	3,599	3,972	4,498	5,171	5,200	5,401	5,612	5,740	6,037
Cashflow statement									
Operating activities	(229)	77	76	191	466	474	502	662	782
Investing activities	(294)	(417)	(249)	(242)	(262)	(284)	(216)	(198)	(206)
Financing activities	486	352	161	80	(168)	(229)	(274)	(464)	(346)
Change in cash	(37)	11	(13)	29	36	(39)	11	1	230
Ending cash balance	17	28	16	44	80	41	53	53	284
Key fundamental ratios									
Liquidity ratios									
Current ratio (x)	1.3	1.2	1.2	1.3	1.9	1.9	2.0	2.0	2.3
Quick ratio (x)	1.1	1.0	1.1	1.2	1.8	1.8	1.9	1.9	2.2
Profitability ratios									
GP Margin	33.0%	32.5%	31.6%	38.2%	38.6%	39.1%	38.5%	39.2%	39.9%
Operating Margins	6.1%	2.9%	6.5%	12.9%	14.6%	14.5%	13.8%	14.8%	15.4%
EBITDA Margin	13.4%	10.4%	13.3%	20.1%	20.8%	20.4%	19.3%	20.1%	20.7%
Net Margin	4.7%	0.9%	3.5%	6.8%	8.0%	9.4%	10.1%	12.2%	13.7%
Return on assets	2.4%	0.5%	1.8%	3.7%	4.6%	5.9%	6.8%	8.6%	9.8%
Return on equity	5.8%	1.3%	5.6%	12.1%	14.2%	16.0%	16.2%	17.8%	17.9%
Leverage ratio									
Debt / equity (x)	1.2	1.5	1.5	1.6	1.3	1.0	0.7	0.5	0.3
Market/valuation ratios									
EV/sales (x)	2.7	2.6	2.1	3.8	3.3	2.9	2.6	2.3	2.0
EV/EBITDA (x)	20.8	26.1	16.8	19.5	16.2	14.6	13.6	11.4	10.0
EPS (SAR)	0.9	0.2	0.8	2.0	2.6	3.4	4.0	5.3	6.2
BVPS (SAR)	13.4	13.7	14.8	16.5	19.1	22.5	26.6	31.8	37.1
Market price (SAR)	35.1	31.7	25.5	83.3	83.5	83.5	83.5	83.5	83.5
Market-Cap (SAR mn)	3,226	2,913	2,347	7,667	7,685	7,685	7,685	7,685	7,685
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.2%	1.8%
P/E ratio (x)	39.3	169.4	31.2	42.6	32.1	24.5	20.6	15.8	13.4
P/BV ratio (x)	2.6	2.3	1.7	5.0	4.4	3.7	3.1	2.6	2.3

Sources: Aljazira Capital, Company Financials





RESEARCH DIVISION

Head of Sell-Side Research - AGM
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

RESEARCH
DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068